Literature DB >> 17321857

Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis.

Michael E Pichichero1, Janet R Casey.   

Abstract

BACKGROUND: Recent analysis of clinical data and a clearer understanding of the role of chemical structure in the development of cross-reactivity indicate that the increased risk of an allergic reaction to a cephalosporin in penicillin-allergic patients is smaller than previously postulated.
METHOD: Medline and EMBASE databases were searched with the keywords: cephalosporin, penicillin, allergy, and cross-sensitivity for the years 1960 through 2005. Among 219 articles retrieved, 9 served as source material for this evidence-based meta-analysis.
RESULTS: A significant increase in allergic reactions to cephalothin (odds ratio [OR] = 2.5; 95% confidence interval [CI] = 1.1 to 5.5), cephaloridine (OR = 8.7; CI = 5.9 to 12.8), and cephalexin (OR = 5.8; CI = 3.6 to 9.2), and all first generation cephalosporins plus cefamandole (OR = 4.8; CI = 3.7 to 6.2) were observed in penicillin allergic patients; no increase was observed with second generation cephalosporins (OR = 1.1; CI, 0.6 to 2.1) or third generation cephalosporins (OR = 0.5; CI = 0.2 to 1.1). Clinical challenges, skin testing, and monoclonal antibody studies point to the paramount importance of similarities in side chain structure to predict cross-allergy between cephalosporins and penicillins.
CONCLUSION: First-generation cephalosporins have cross-allergy with penicillins, but cross-allergy is negligible with second- and third-generation cephalosporins. Particular emphasis should be placed on the role of chemical structure in determining the risk of cross-reactivity between specific agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17321857     DOI: 10.1016/j.otohns.2006.10.007

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  30 in total

Review 1.  In patients allergic to penicillin, consider second and third generation cephalosporins for life threatening infections.

Authors:  Scott Pegler; Brendan Healy
Journal:  BMJ       Date:  2007-11-10

2.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

Review 3.  Peri-operative anaphylaxis.

Authors:  Linda Nel; Efrem Eren
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

4.  Improving Clinical Outcomes in Patients With Methicillin-Sensitive Staphylococcus aureus Bacteremia and Reported Penicillin Allergy.

Authors:  Kimberly G Blumenthal; Robert A Parker; Erica S Shenoy; Rochelle P Walensky
Journal:  Clin Infect Dis       Date:  2015-05-19       Impact factor: 9.079

5.  The Culture of Carbapenem Overconsumption: Where Does It Begin? Results of a Single-Center Survey.

Authors:  Bryan T Mogle; Robert W Seabury; Zachary Jones; Christopher D Miller; Jeffrey M Steele
Journal:  Hosp Pharm       Date:  2018-05-08

Review 6.  Skin testing for Beta-lactam antibiotics: impact of the availability of a major determinant.

Authors:  Fatima S Khan; Michael E Weiss
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

Review 7.  Diagnosis and management of immediate hypersensitivity reactions to cephalosporins.

Authors:  Scott D Dickson; Kimberly C Salazar
Journal:  Clin Rev Allergy Immunol       Date:  2013-08       Impact factor: 8.667

8.  Impact of a clinical guideline for prescribing antibiotics to inpatients reporting penicillin or cephalosporin allergy.

Authors:  Kimberly G Blumenthal; Erica S Shenoy; Christy A Varughese; Shelley Hurwitz; David C Hooper; Aleena Banerji
Journal:  Ann Allergy Asthma Immunol       Date:  2015-06-09       Impact factor: 6.347

Review 9.  Cross-Reactivity among Beta-Lactams.

Authors:  Antonino Romano; Francesco Gaeta; Maria Francisca Arribas Poves; Rocco Luigi Valluzzi
Journal:  Curr Allergy Asthma Rep       Date:  2016-03       Impact factor: 4.806

Review 10.  Pediatric sinusitis.

Authors:  Ricardo Tan; Sheldon Spector
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.